Real-world experience of Quantiferon-CMV directed prophylaxis in lung transplant recipients
- 19 May 2022
- journal article
- research article
- Published by Elsevier BV in The Journal of Heart and Lung Transplantation
- Vol. 41 (9), 1258-1267
- https://doi.org/10.1016/j.healun.2022.05.004
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Long-term efficacy and safety of 12 months of valganciclovir prophylaxis compared with 3 months after lung transplantation: A single-center, long-term follow-up analysis from a randomized, controlled cytomegalovirus prevention trialThe Journal of Heart and Lung Transplantation, 2011
- Cytomegalovirus disease among donor-positive/recipient-negative lung transplant recipients in the era of valganciclovir prophylaxisThe Journal of Heart and Lung Transplantation, 2010
- An International Survey of Cytomegalovirus Management Practices in Lung TransplantationTransplantation, 2010
- Cytomegalovirus Pneumonitis Is a Risk for Bronchiolitis Obliterans Syndrome in Lung TransplantationAmerican Journal of Respiratory and Critical Care Medicine, 2010
- Cytomegalovirus Prevention in High-risk Lung Transplant Recipients: Comparison of 3- vs 12-Month Valganciclovir TherapyThe Journal of Heart and Lung Transplantation, 2009
- A Multicenter Study of Valganciclovir Prophylaxis up to Day 120 in CMV-Seropositive Lung Transplant RecipientsAmerican Journal of Transplantation, 2009
- Cell-Mediated Immunity to Predict Cytomegalovirus Disease in High-Risk Solid Organ Transplant RecipientsAmerican Journal of Transplantation, 2009
- Immunobiology of Human Cytomegalovirus: from Bench to BedsideClinical Microbiology Reviews, 2009
- Ganciclovir/Valganciclovir Prophylaxis Decreases Cytomegalovirus-Related Events and Bronchiolitis Obliterans Syndrome after Lung TransplantationClinical Infectious Diseases, 2008
- Extended Ganciclovir Prophylaxis in Lung TransplantationThe Journal of Heart and Lung Transplantation, 2005